Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas
- PMID: 21498106
- DOI: 10.1016/j.oraloncology.2011.03.020
Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas
Abstract
The significance of epidermal growth factor receptor (EGFR) signaling is well studied in a number of different tumors, but limited data is available with regard to head and neck squamous cell carcinoma (HNSCC). Since anti-EGFR therapies are currently under investigation in these malignancies as well, comprehensive information about the alteration of EGFR in HNSCC is necessary to design the most appropriate therapeutic protocols. We examined retrospectively the gene copy number of EGFR by FISH and the protein expression by immunohistochemistry using different epitope-specific antibodies in paraffin-embedded primary tumors of five different regions, from 71 HNSCC patients who had not been treated with anti-EGFR therapy. In seven cases corresponding lymph node metastases were also available for comparative analyses. We also determined the mutational status of tyrosine kinase (TK) domain (exon 19 and 21) and the extracellular deletion mutation (vIII) of EGFR, the KRAS mutation at codon 12 and the presence of HPV infection. Eight of the 71 cases (11.3%) showed EGFR gene amplification (most of them localized into the hypopharyngeal region) and the increased gene copy number (amplification+polysomy) was 43.7%. Despite pronounced intratumoral heterogeneity of EGFR protein expression being found, the high EGFR expression correlated with poor prognosis. On the other hand, the phosphorylation of EGFR was associated with prolonged survival. No mutations in the TK domain of EGFR were found in any of the HNSCC patients and only two cases were KRAS mutant at codon 12. We detected vIII deletion mutation of EGFR in 21% of the samples, but there was no statistically significant correlation between the presence of vIII mutant form and patient survival. EGFR vIII mutation was, however, associated with increased gene copy number. Fourteen of 71 cases (19.7%) were HPV-positive and the incidence of infection showed a decreasing tendency from the oral cavity towards the larynx. Interestingly, in contrast to previous findings, we could not observe improved survival in HPV-positive patients compared to non-infected patients, most probably due to the fact that the majority of these HNSCC patients were smokers and alcohol consumers. In conclusion, we found that increased EGFR protein levels and gene copy numbers (not gene amplification alone) have prognostic significance in the investigated HNSCC patient population. However, the relatively high incidence of the EGFR-vIII mutant form warrants careful therapeutic decision-making when choosing between different anti-EGFR treatment options.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.Neoplasma. 2012;59(5):508-15. doi: 10.4149/neo_2012_065. Neoplasma. 2012. PMID: 22668015
-
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.J Clin Oncol. 2006 Sep 1;24(25):4170-6. doi: 10.1200/JCO.2006.07.2587. J Clin Oncol. 2006. PMID: 16943533
-
Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.Oncologist. 2009 Sep;14(9):900-8. doi: 10.1634/theoncologist.2009-0058. Epub 2009 Sep 2. Oncologist. 2009. PMID: 19726454
-
Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29. Pathol Res Pract. 2011. PMID: 21531084 Review.
-
Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review.In Vivo. 2017 Jan 2;31(1):23-34. doi: 10.21873/invivo.11020. In Vivo. 2017. PMID: 28064216 Free PMC article. Review.
Cited by
-
Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis.Eur J Clin Pharmacol. 2012 May;68(5):561-9. doi: 10.1007/s00228-011-1194-1. Epub 2012 Jan 10. Eur J Clin Pharmacol. 2012. PMID: 22231637
-
Correlations between prognosis and regional biomarker profiles in head and neck squamous cell carcinomas.Pathol Oncol Res. 2015 Jul;21(3):643-50. doi: 10.1007/s12253-014-9869-4. Epub 2014 Dec 31. Pathol Oncol Res. 2015. PMID: 25547827
-
Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.Clin Med Insights Ear Nose Throat. 2012 Apr 3;5:1-16. doi: 10.4137/CMENT.S5129. Clin Med Insights Ear Nose Throat. 2012. PMID: 24179404 Free PMC article. Review.
-
Epstein-Barr Virus-Oral Bacterial Link in the Development of Oral Squamous Cell Carcinoma.Pathogens. 2020 Dec 18;9(12):1059. doi: 10.3390/pathogens9121059. Pathogens. 2020. PMID: 33352891 Free PMC article. Review.
-
Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma.Head Neck Pathol. 2013 Dec;7(4):344-55. doi: 10.1007/s12105-013-0447-y. Epub 2013 May 4. Head Neck Pathol. 2013. PMID: 23645351 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous